Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Fintel reports that on July 29, 2025, William Blair downgraded their outlook for Neogen (NasdaqGS:NEOG) from Outperform to ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

Data analytics firm Verisk said on Wednesday it will buy AccuLynx, which makes software for roofing contractors, for $2.35 ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

But while many analysts presented a bullish case for the company's turnaround, not all investors are sold on Niccol and his ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

Gain insights into Watsco, Inc.'s Q2 2025 performance, including record margins, tech-driven growth, and its strategic focus on overcoming market ...

Data analytics provider Verisk is acquiring SaaS platform AccuLynx for $2.35bn in cash, the company said in a statement. The ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...